Paper36901764
A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition.
Barrios-Bernal P and 4 others. Int J Mol Sci, 2023. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition. Papers, record 36901764. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36901764
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Metformin | Major topic |
| Humans | |
| Apoptosis | |
| Cell Line | |
| Mutation | |
| Proto-Oncogene Proteins c-akt | |
| Proto-Oncogene Proteins p21(ras) | |
| Ribosomal Protein S6 Kinases, 70-kDa | |
| TOR Serine-Threonine Kinases | |
| Piperazines | |
| Pyridines | |
| Pyrimidines |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33294856 | Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer. | Cell Rep Med | 2020 | https://conductscience.org/library/papers/33294856 | PubMed |
| 2 | 27519177 | Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer. | BMC Cancer | 2016 | https://conductscience.org/library/papers/27519177 | PubMed |
| 3 | 35402614 | Gypenoside-Induced Apoptosis via the PI3K/AKT/mTOR Signaling Pathway in Bladder Cancer. | Biomed Res Int | 2022 | https://conductscience.org/library/papers/35402614 | PubMed |
| 4 | 26359221 | Metformin: risk-benefit profile with a focus on cancer. | Expert Opin Drug Saf | 2015 | https://conductscience.org/library/papers/26359221 | PubMed |
| 5 | 21540236 | Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. | Cancer Res | 2011 | https://conductscience.org/library/papers/21540236 | PubMed |
| 6 | 33022831 | KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC). | Thorac Cancer | 2020 | https://conductscience.org/library/papers/33022831 | PubMed |
| 7 | 23362830 | Metformin induces cytotoxicity by down-regulating thymidine phosphorylase and excision repair cross-complementation 1 expression in non-small cell lung cancer cells. | Basic Clin Pharmacol Toxicol | 2013 | https://conductscience.org/library/papers/23362830 | PubMed |
| 8 | 35337178 | Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial-Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells. | Pharmaceuticals (Basel) | 2022 | https://conductscience.org/library/papers/35337178 | PubMed |
| 9 | 26673006 | Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. | Oncotarget | 2016 | https://conductscience.org/library/papers/26673006 | PubMed |
| 10 | 34244683 | Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment. | Nat Rev Cancer | 2021 | https://conductscience.org/library/papers/34244683 | PubMed |
| 11 | 31486833 | Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial. | JAMA Oncol | 2019 | https://conductscience.org/library/papers/31486833 | PubMed |
| 12 | 31276344 | Mutational profile by targeted next generation sequencing of non-small cell lung cancer in the Mexican population. | Salud Publica Mex | 2019 | https://conductscience.org/library/papers/31276344 | PubMed |
| 13 | 34675734 | Spotlight on Sotorasib (AMG 510) for KRAS G12C Positive Non-Small Cell Lung Cancer. | Lung Cancer (Auckl) | 2021 | https://conductscience.org/library/papers/34675734 | PubMed |
| 14 | 32540954 | AMG 510 Shows Activity beyond NSCLC. | Cancer Discov | 2020 | https://conductscience.org/library/papers/32540954 | PubMed |
| 15 | 28481268 | Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies. | Cancers (Basel) | 2017 | https://conductscience.org/library/papers/28481268 | PubMed |
| 16 | 32750661 | KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis. | Cancer Treat Res Commun | 2020 | https://conductscience.org/library/papers/32750661 | PubMed |
| 17 | 26847819 | Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase. | Mol Med Rep | 2016 | https://conductscience.org/library/papers/26847819 | PubMed |
| 18 | 23707609 | Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways. | Toxicol Appl Pharmacol | 2013 | https://conductscience.org/library/papers/23707609 | PubMed |
| 19 | 32955176 | KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32955176 | PubMed |
| 20 | 30327306 | KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30327306 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42240478 | Targeting GSTZ1 Sensitizes KRASG12C-Mutant Lung Cancer Cells by Overcoming Glutathione and Glycolysis Pathway Rewiring. | Cancer Res Commun | 2026 | https://conductscience.org/library/papers/42240478 | PubMed |
| 41824068 | The clinicopathologic characteristics and outcomes of uncommon KRAS mutations in patients with non-small cell lung cancer. | Virchows Arch | 2026 | https://conductscience.org/library/papers/41824068 | PubMed |
| 40756996 | Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40756996 | PubMed |
| 39202556 | Metformin in Chemoprevention of Lung Cancer: A Retrospective Population-Based Cohort Study in Lithuania. | Medicina (Kaunas) | 2024 | https://conductscience.org/library/papers/39202556 | PubMed |
| 37627169 | Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37627169 | PubMed |
Genes20
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36901764
GET https://conductscience.org/api/papers/v1/36901764/references?page=2